Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …

Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …

Background Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with
efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily
Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …

Abstract iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus
obinutuzumab (n= 113) versus chlorambucil plus obinutuzumab (n= 116) as first-line …

Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for
patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal …